Evaxion A/S EVAX
3.00 USD +0.24 (+8.70%)
At closeNov 6, 2026, 5:53 PM EST
2.92 -0.08 -2.67%
After hours · Nov 6, 5:53 PM ET
2.71 Day range 3.21
2.76 52-week range 6.63
- YTD
- -37.11%
- 1 year
- -52.08%
News
benzinga.com Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2…
benzinga.com Evaxion To Demonstrate New Data For EVX-04 Vaccine At American Society Of Hematology Annual Meeting Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an…
globenewswire.com Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology…
globenewswire.com Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting New data from the phase 2 trial with EVX-01 to be presented in both an oral and poster session COPENHAGEN, Denmark, November 3, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
benzinga.com Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…- benzinga.com Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
benzinga.com Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of…
benzinga.com Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
- benzinga.com Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™…
- benzinga.com Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026 Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into…
- benzinga.com Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation,…
- benzinga.com Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026 New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking…
- benzinga.com Evaxion Says AI-Immunology-Developed EVX-04 Shows Immune Activation And Targeted Cell-Killing In Preclinical Acute Myeloid Leukemia Data EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026 Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio…
benzinga.com Evaxion Biotech Q1 EPS $(0.01) Beats $(0.23) Estimate Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.23) by 95.65 percent. This is unchanged from the same period last year.
benzinga.com Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO),…
benzinga.com HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
benzinga.com Evaxion's Announces Its Data Demonstrating AI-Immunology Traces, Selects Therapeutically Relevant Vaccine Targets; 88% Vaccine Targets Trigger Tumor-Specific Immune Response Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™…- benzinga.com Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform…
- benzinga.com Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01 EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in…
benzinga.com Lake Street Maintains Buy on Evaxion, Lowers Price Target to $9 Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and lowers the price target from $11 to $9.- benzinga.com HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
benzinga.com Evaxion Earnings Report: Q4 Overview - benzinga.com Evaxion Biotech Q4 EPS $(0.02) Beats $(0.30) Estimate Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.30) by 93.27 percent. This is a 90.48 percent increase over losses of…
benzinga.com Insights into Evaxion Q4 Earnings 
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com Evaxion Biotech's Earnings: A Preview 
benzinga.com Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.- benzinga.com Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted…
- benzinga.com Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program…
- benzinga.com Evaxion Announces New Data Exploring Immune Responses Following Treatment With AI-designed Personalized Cancer Vaccine EVX-01 Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment…
- benzinga.com Evaxion Biotech Q3 EPS $0.01 Beats $(0.21) Estimate, Sales $7.492M Beat $2.500M Estimate Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.21) by 104.76 percent. This is a 125 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com What's Next: Evaxion Biotech's Earnings Preview
- benzinga.com Evaxion Expands R&D Pipeline With Addition EVX-04, AI-Designed Precision Cancer Vaccine Candidate Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platformEVX-04 is a therapeutic cancer vaccine candidate…
benzinga.com This Draganfly Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday 
benzinga.com Edward Jones Initiates Coverage On Evaxion with Buy Rating, Announces Price Target of $10 Edward Jones analyst Soumit Roy initiates coverage on Evaxion (NASDAQ:EVAX) with a Buy rating and announces Price Target of $10.- benzinga.com Evaxion A/S Appoints Helen Tayton-Martin CEO, Effective Nov. 24 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has appointed Dr Helen Tayton-Martin as new Chief Executive…
- benzinga.com Lake Street Maintains Buy on Evaxion, Raises Price Target to $11 Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price target from $6 to $11.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Evaxion A/S Reports Two-Year Phase 2 Data Showing Results For Its Personalized Cancer Vaccine EVX-01 In Advanced Melanoma. Study Showed A 75% Objective Response Rate With 4 Of 16 Patients Achieving Complete Responses And 92% Maintaining Durable Responses At 24 Months With No Relapses Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year unprecedented clinical efficacy data of its…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Evaxion Will Present Comprehensive Phase 2 Trial Data For Its Lead Cancer Vaccine EVX-01 At The ESMO Congress 2025 In Berlin Oct 17–21, 2025. Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing…